First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Prexasertib data worsen again, and biomarkers are up in the air.
